1.
Product Overview
1.1.
Market Definition
1.2.
Scope of the Market
1.2.1.
Markets Covered
1.2.2.
Years Considered for Study
1.2.3.
Key Market Segmentations
2.
Research Methodology
2.1.
Objective of the Study
2.2.
Baseline Methodology
2.3.
Key Industry Partners
2.4.
Major Association and Secondary Sources
2.5.
Forecasting Methodology
2.6.
Data Triangulation & Validation
2.7. Assumptions
and Limitations
3.
Executive Summary
3.1.
Overview of the Market
3.2.
Overview of Key Market Segmentations
3.3.
Overview of Key Market Players
3.4.
Overview of Key Regions/Countries
3.5.
Overview of Market Drivers, Challenges, and Trends
4.
Voice of Customer
5. Global
Sickle Cell Disease Treatment Market Outlook
5.1.
Market Size & Forecast
5.1.1.
By Value
5.2.
Market Share & Forecast
5.2.1. By Treatment
(Blood Transfusion, Pharmacotherapy,
Bone Marrow Transplant)
5.2.2.
By End-Use (Hospitals, Specialty Clinics. Others)
5.2.3.
By Company (2024)
5.2.4.
By Region
5.3.
Market Map
6. North
America Sickle Cell Disease Treatment Market Outlook
6.1.
Market Size & Forecast
6.1.1.
By Value
6.2.
Market Share & Forecast
6.2.1. By Treatment
6.2.2. By End-Use
6.2.3.
By Country
6.3.
North America: Country Analysis
6.3.1.
United States Sickle Cell Disease Treatment Market Outlook
6.3.1.1.
Market Size & Forecast
6.3.1.1.1.
By Value
6.3.1.2.
Market Share & Forecast
6.3.1.2.1.
By Treatment
6.3.1.2.2.
By End-Use
6.3.2.
Mexico Sickle Cell Disease Treatment Market Outlook
6.3.2.1.
Market Size & Forecast
6.3.2.1.1.
By Value
6.3.2.2.
Market Share & Forecast
6.3.2.2.1.
By Treatment
6.3.2.2.2.
By End-Use
6.3.3.
Canada Sickle Cell Disease Treatment Market Outlook
6.3.3.1.
Market Size & Forecast
6.3.3.1.1.
By Value
6.3.3.2.
Market Share & Forecast
6.3.3.2.1.
By Treatment
6.3.3.2.2.
By End-Use
7. Europe
Sickle Cell Disease Treatment Market Outlook
7.1.
Market Size & Forecast
7.1.1.
By Value
7.2.
Market Share & Forecast
7.2.1. By Treatment
7.2.2. By End-Use
7.2.3.
By Country
7.3.
Europe: Country Analysis
7.3.1.
France Sickle Cell Disease Treatment Market Outlook
7.3.1.1.
Market Size & Forecast
7.3.1.1.1.
By Value
7.3.1.2.
Market Share & Forecast
7.3.1.2.1.
By Treatment
7.3.1.2.2.
By End-Use
7.3.2.
Germany Sickle Cell Disease Treatment Market Outlook
7.3.2.1.
Market Size & Forecast
7.3.2.1.1.
By Value
7.3.2.2.
Market Share & Forecast
7.3.2.2.1.
By Treatment
7.3.2.2.2.
By End-Use
7.3.3.
United Kingdom Sickle Cell Disease Treatment Market Outlook
7.3.3.1.
Market Size & Forecast
7.3.3.1.1.
By Value
7.3.3.2.
Market Share & Forecast
7.3.3.2.1.
By Treatment
7.3.3.2.2.
By End-Use
7.3.4.
Italy Sickle Cell Disease Treatment Market Outlook
7.3.4.1.
Market Size & Forecast
7.3.4.1.1.
By Value
7.3.4.2.
Market Share & Forecast
7.3.4.2.1.
By Treatment
7.3.4.2.2.
By End-Use
7.3.5.
Spain Sickle Cell Disease Treatment Market Outlook
7.3.5.1.
Market Size & Forecast
7.3.5.1.1.
By Value
7.3.5.2.
Market Share & Forecast
7.3.5.2.1.
By Treatment
7.3.5.2.2.
By End-Use
8. Asia-Pacific
Sickle Cell Disease Treatment Market Outlook
8.1.
Market Size & Forecast
8.1.1.
By Value
8.2.
Market Share & Forecast
8.2.1. By Treatment
8.2.2. By End-Use
8.2.3.
By Country
8.3.
Asia-Pacific: Country Analysis
8.3.1.
China Sickle Cell Disease Treatment Market Outlook
8.3.1.1.
Market Size & Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share & Forecast
8.3.1.2.1.
By Treatment
8.3.1.2.2.
By End-Use
8.3.2.
India Sickle Cell Disease Treatment Market Outlook
8.3.2.1.
Market Size & Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share & Forecast
8.3.2.2.1.
By Treatment
8.3.2.2.2.
By End-Use
8.3.3.
South Korea Sickle Cell Disease Treatment Market Outlook
8.3.3.1.
Market Size & Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share & Forecast
8.3.3.2.1.
By Treatment
8.3.3.2.2.
By End-Use
8.3.4.
Japan Sickle Cell Disease Treatment Market Outlook
8.3.4.1.
Market Size & Forecast
8.3.4.1.1.
By Value
8.3.4.2.
Market Share & Forecast
8.3.4.2.1.
By Treatment
8.3.4.2.2.
By End-Use
8.3.5.
Australia Sickle Cell Disease Treatment Market Outlook
8.3.5.1.
Market Size & Forecast
8.3.5.1.1.
By Value
8.3.5.2.
Market Share & Forecast
8.3.5.2.1.
By Treatment
8.3.5.2.2.
By End-Use
9. South
America Sickle Cell Disease Treatment Market Outlook
9.1.
Market Size & Forecast
9.1.1.
By Value
9.2.
Market Share & Forecast
9.2.1. By Treatment
9.2.2. By End-Use
9.2.3.
By Country
9.3.
South America: Country Analysis
9.3.1.
Brazil Sickle Cell Disease Treatment Market Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By Treatment
9.3.1.2.2.
By End-Use
9.3.2.
Argentina Sickle Cell Disease Treatment Market Outlook
9.3.2.1.
Market Size & Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share & Forecast
9.3.2.2.1.
By Treatment
9.3.2.2.2.
By End-Use
9.3.3.
Colombia Sickle Cell Disease Treatment Market Outlook
9.3.3.1.
Market Size & Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share & Forecast
9.3.3.2.1.
By Treatment
9.3.3.2.2.
By End-Use
10. Middle
East and Africa Sickle Cell Disease Treatment Market Outlook
10.1.
Market Size & Forecast
10.1.1.
By Value
10.2.
Market Share & Forecast
10.2.1. By Treatment
10.2.2. By End-Use
10.2.3.
By Country
10.3.
MEA: Country Analysis
10.3.1.
South Africa Sickle Cell Disease Treatment Market Outlook
10.3.1.1.
Market Size & Forecast
10.3.1.1.1.
By Value
10.3.1.2.
Market Share & Forecast
10.3.1.2.1.
By Treatment
10.3.1.2.2.
By End-Use
10.3.2.
Saudi Arabia Sickle Cell Disease Treatment Market Outlook
10.3.2.1.
Market Size & Forecast
10.3.2.1.1.
By Value
10.3.2.2.
Market Share & Forecast
10.3.2.2.1.
By Treatment
10.3.2.2.2.
By End-Use
10.3.3.
UAE Sickle Cell Disease Treatment Market Outlook
10.3.3.1.
Market Size & Forecast
10.3.3.1.1.
By Value
10.3.3.2.
Market Share & Forecast
10.3.3.2.1.
By Treatment
10.3.3.2.2.
By End-Use
11.
Market Dynamics
11.1.
Drivers
11.2.
Challenges
12.
Market Trends & Developments
12.1.
Merger & Acquisition (If Any)
12.2.
Product Launches (If Any)
12.3.
Recent Developments
13.
Disruptions:
Conflicts, Pandemics and Trade Barriers
14.
Porters Five Forces Analysis
14.1.
Competition in the Industry
14.2.
Potential of New Entrants
14.3.
Power of Suppliers
14.4.
Power of Customers
14.5.
Threat of Substitute Products
15.
Competitive Landscape
15.1.
Novartis AG
15.1.1. Business
Overview
15.1.2. Company
Snapshot
15.1.3. Products
& Services
15.1.4. Financials
(As Reported)
15.1.5. Recent
Developments
15.1.6. Key
Personnel Details
15.1.7. SWOT
Analysis
15.2.
Pfizer Inc.
15.3.
Bluebird Bio, Inc
15.4.
GlycoMimetics
15.5.
Emmaus Medical, Inc
15.6.
Bristol-Myers Squibb Company
15.7.
CRISPR Therapeutics
15.8.
Graphite Bio, Inc.
16.
Strategic Recommendations
17. About
Us & Disclaimer